Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWC202206 and DWC202207 in Hypertension and Dyslipidemia
NCT05643508Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of DWC202206 and DWC202207 in hypertension (HTN) and hyperlipidemia (3 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Mean Sitting Systolic Blood Pressure at 8 weeks and Low-Density Lipoprotein Cholesterol at 8 weeks. Started Feb 2023; status: completed.
02
Drugs
DWC202206DWC202207
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on NCT05643508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05643508.